Efficacy and safety of PARP inhibitors in the treatment of advanced ovarian cancer: An updated systematic review and meta-analysis of randomized controlled trials

•PARP inhibitors showed more survival benefits than control therapy, irrespective of BRCA status.•Performance of the PARP inhibitors declines slightly due to increased risks of selected adverse events.•Most of the treatment-related toxicities occurred during the early stage.•Most toxicities were managed by dose interruption or dose reduction, rather than dose discontinuation.